title: Pharmacokinetics of oral rufinamide in dogs.
abstract: The objective of this study was to determine the pharmacokinetic properties and short-term adverse effect profile of single-dose oral rufinamide in healthy dogs. Six healthy adult dogs were included in the study. The pharmacokinetics of rufinamide were calculated following administration of a single mean oral dose of 20.0 mg/kg (range 18.6-20.8 mg/kg). Plasma rufinamide concentrations were determined using high-performance liquid chromatography, and pharmacokinetic data were analyzed using commercial software. No adverse effects were observed. The mean terminal half-life was 9.86 ± 4.77 h. The mean maximum plasma concentration was 19.6 ± 5.8 μg/mL, and the mean time to maximum plasma concentration was 9.33 ± 4.68 h. Mean clearance was 1.45 ± 0.70 L/h. The area under the curve (to infinity) was 411 ± 176 μg · h/mL. Results of this study suggest that rufinamide given orally at 20 mg/kg every 12 h in healthy dogs should result in a plasma concentration and half-life sufficient to achieve the therapeutic level extrapolated from humans without short-term adverse effects. Further investigation into the efficacy and long-term safety of rufinamide in the treatment of canine epilepsy is warranted.
authors: Department of Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA 99163, USA. hwright@vetmed.wsu.edu
authors: H M
authors: HM
authors: Wright
authors: A V
authors: AV
authors: Chen
authors: S E
authors: SE
authors: Martinez
authors: N M
authors: NM
authors: Davies
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000927:Anticonvulsants / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D004285:Dogs / Q000097:blood*; D005260:Female; D006207:Half-Life; D008297:Male; D010865:Pilot Projects; D014230:Triazoles / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000927:Anticonvulsants; D014230:Triazoles; C079703:rufinamide